Skip to main content
Fig. 1 | BMC Infectious Diseases

Fig. 1

From: Indirect comparison of 48-week efficacy and safety of long-acting cabotegravir and rilpivirine maintenance every 8 weeks with daily oral standard of care antiretroviral therapy in participants with virologically suppressed HIV-1-infection

Fig. 1

Diagram of studies included in indirect comparison. CAB cabotegravir, Q4W every 4 weeks, Q8W every 8 weeks, RPV rilpivirine, SoC standard of care, ATLAS/FLAIR antiretroviral therapy as long-acting suppression/first long-acting injectable regimen, ATLAS-2M antiretroviral therapy as long-acting suppression every 2 months

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us